Having trouble accessing articles? Reset your cache.

Ketotransdel: Final Phase III data

Final data from the intent-to-treat (ITT) population (n=361) of a double-blind, U.S. Phase III trial showed that 1g thrice-daily topical Ketotransdel for 7 days missed the primary endpoint of

Read the full 299 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE